German vaccine maker CureVac surges almost 250% in Nasdaq debut
Shares of German biotech company CureVac, which is developing a leading coronavirus vaccine candidate, rocketed Friday in its first day of trading in New York after raising more than $200 million in an initial public offering. The company, trading on the Nasdaq under the “CVAC” ticket, finished at $55.90, up almost 250 percent from its introductory price of $16 a […]
» Read more